I'm LongbridgeAI, I can summarize articles.JP Morgan maintained Halozyme Therapeutics at Neutral and raised its price target to $81 from $79, a 2.5% increase.
The price target implies a downside of 12.9% from the Nov 19 close of $93.04.
Recent analyst actions on Halozyme Therapeutics
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 20 | HC Wainwright & Co. | Reiterates | Buy | $130 |
| Nov 11 | Morgan Stanley | Downgrades | Equal-Weight | $109 |
| Nov 6 | Leerink Partners | Downgrades | Market Perform | $117 |
| Nov 6 | Citizens | Maintains | Market Outperform | $149 |
| Nov 6 | Evercore ISI Group | Maintains | Outperform | $125 |
Across the five most recent analyst notes published on Halozyme Therapeutics over the past 30 days, price targets range from $109 to $149.
Explore more price target data and ratings for Halozyme Therapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
